Multiple Myeloma
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Access global market intelligence on multiple myeloma drug development, clinical trials, regulatory approvals, and competitive landscapes.
Showing 1–6 of 6 articles
Quick answer
NovaPharmaNews Multiple Myeloma hub for FDA covers 6 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA MRD guidance in multiple myeloma: what BD teams should track
GSK’s Blenrep returns to the US market after FDA approves resubmission
GSK Blenrep wins FDA approval in relapsed multiple myeloma
Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial
ASCO 2026: Key Oncology Data Readouts to Watch
FDA Approves Talvey (talquetamab) for Relapsed Multiple Myeloma
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.